Abstract
Congestive heart failure (CHF) is characterized not only by profound abnormalities in the haemodynamic profile but also by changes in sympathetic cardiovascular function. These neurogenic abnormalities are important features of the disease that can affect the prognosis of CHF and to become a target for therapeutic intervention. This article addresses 4 major issues. It will first examine the evidence that a hyperadrenergic state is a hallmark of CHF, based on data collected via indirect (plasma norepinephrine, power spectral analysis of the heart rate signal) and direct (microneurography, norepinephrine spillover, radioimaging techniques visualizing myocardial neural network) approaches. It will then provide an overview on the central, reflex and metabolic factors potentially responsible for the phenomenon. The review also analyses the clinical consequences of the adrenergic alteration, with particular emphasis on the effects of the sympathetic overdrive on disease progression, arrhythmogenic threshold, adverse clinical outcomes as well as sudden death. The final part of the review will examine the therapeutic implications of the above mentioned findings and discuss the effects of pharmacological and non- pharmacological interventions on the sympathetic abnormalities of the heart failure state.
Keywords: Heart failure, sympathetic nervous system, prognosis, baroreflex, drugs
Current Vascular Pharmacology
Title: Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Volume: 7 Issue: 2
Author(s): Guido Grassi, Gino Seravalle, Fosca Quarti-Trevano and Raffaella Dell'Oro
Affiliation:
Keywords: Heart failure, sympathetic nervous system, prognosis, baroreflex, drugs
Abstract: Congestive heart failure (CHF) is characterized not only by profound abnormalities in the haemodynamic profile but also by changes in sympathetic cardiovascular function. These neurogenic abnormalities are important features of the disease that can affect the prognosis of CHF and to become a target for therapeutic intervention. This article addresses 4 major issues. It will first examine the evidence that a hyperadrenergic state is a hallmark of CHF, based on data collected via indirect (plasma norepinephrine, power spectral analysis of the heart rate signal) and direct (microneurography, norepinephrine spillover, radioimaging techniques visualizing myocardial neural network) approaches. It will then provide an overview on the central, reflex and metabolic factors potentially responsible for the phenomenon. The review also analyses the clinical consequences of the adrenergic alteration, with particular emphasis on the effects of the sympathetic overdrive on disease progression, arrhythmogenic threshold, adverse clinical outcomes as well as sudden death. The final part of the review will examine the therapeutic implications of the above mentioned findings and discuss the effects of pharmacological and non- pharmacological interventions on the sympathetic abnormalities of the heart failure state.
Export Options
About this article
Cite this article as:
Grassi Guido, Seravalle Gino, Quarti-Trevano Fosca and Dell'Oro Raffaella, Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications, Current Vascular Pharmacology 2009; 7 (2) . https://dx.doi.org/10.2174/157016109787455699
DOI https://dx.doi.org/10.2174/157016109787455699 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Significance of Aspirin and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Interventions
Current Vascular Pharmacology Determination of Residual Solvents in Eprosartan Mesylate by Static Headspace Gas Chromatographic Method Optimized by Response Surface Methodology
Current Pharmaceutical Analysis Marine Natural Products as a Promising Source of Therapeutic Compounds to Target Cancer Stem Cells
Current Medicinal Chemistry Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry Direct Renin Inhibition: Promising Treatment in Renoprotection?
Recent Patents on Cardiovascular Drug Discovery Cytostatic Effect of the Nucleoside Analogue 2-Chloroadenosine on Human Prostate Cancer Cell Line
Current Pharmaceutical Analysis Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design MiR-29 Targets PUMA to Suppress Oxygen and Glucose Deprivation/Reperfusion (OGD/R)-induced Cell Death in Hippocampal Neurons
Current Neurovascular Research Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Late Sodium Current Inhibition: The Most Promising Antiarrhythmic Principle in the Near Future?
Current Medicinal Chemistry Blockade of Ser16-Hsp20 Phosphorylation Attenuates Neuroprotection Dependent Upon Bcl-2 and Bax
Current Neurovascular Research Hypothalamic mTOR: The Rookie Energy Sensor
Current Molecular Medicine The Detrimental Effect of Smoking on Female Fertility and IVF Success
Current Women`s Health Reviews Marine Peptides and Related Compounds in Clinical Trial+
Anti-Cancer Agents in Medicinal Chemistry Tetrahydrobiopterin: A Vascular Redox Target to Improve Endothelial Function
Current Vascular Pharmacology Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews Lysosomal Molecules are Up-Regulated in the Articular Cartilage Explants Subjected to Oxidative Stress and in the Cartilage from an Osteoarthritis-Induced Rat Model
Recent Patents on Biomarkers Taking a Systems Approach to the Identification of Novel Therapeutic Targets and Biomarkers
Current Pharmaceutical Biotechnology The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design